Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover Trial.

ABSTRACT:

Importance

Dapagliflozin reduces the urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) decline at a population level, but individuals show a large variation in responses. The n-of-1 trial design allows for direct assessment of treatment effects within an individual, and digital technologies and remote study assessments can reduce clinic visits, ease participant burden, and improve trial efficiency.

Objective

To assess individual UACR responses to dapagliflozin treatment in a decentralized clinical trial and the feasibility of remote data collection.

Design, setting, and participants

This decentralized, randomized, double-blind, placebo-controlled crossover trial using an n-of-1 approach was conducted using data from the Dutch pri

SUBMITTER: Beernink JM 

PROVIDER: S-EPMC11934004 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature